Netherlands· NL-95e6cba93c4e
TALVEY 2 mg/ml oplossing voor injectie
A talquetamab product containing talquetamab, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Talquetamab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX29 (talquetamab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Talquetamab · ATC L01FX29
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of talquetamab costs, country by country.
Normalised to the WHO defined daily dose (4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Talquetamab · price per daily dose (4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$571.23
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TALQUETAMAB
- Manufacturer
- Janssen-Cilag International NV
- Country
- Netherlands (NL)
- ATC code
- L01FX29
- ATC class
- Talquetamab
- Defined daily dose
- 4 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1748
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Talquetamab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandTALVEY 2 mg/mL solution for injectionJanssen-Cilag International NV
- United StatesTALVEYJanssen Biotech, Inc.
- CanadaTALVEYJANSSEN INC
- SwitzerlandTalvey 3 mg/1.5 ml, InjektionslösungJanssen-Cilag AG
- CzechiaTALVEYJanssen-Cilag International N.V., Beerse
- SpainTALVEY 2 MG/ML SOLUCION INYECTABLEJanssen-Cilag International N.V
- FinlandTALVEYJanssen-Cilag International NV
- United KingdomTalvey 3mg/1.5ml solution for injection vialsJanssen-Cilag Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Talvey
- Liechtenstein · Talvey
- Norway · Talvey
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9a2f0c72-7e5e-4eb4-96d1-8c2af58f0699 GET /v1/drugs/9a2f0c72-7e5e-4eb4-96d1-8c2af58f0699?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Talquetamab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131027",
"excipients": [
"AZIJNZUUR (E 260)",
"ETHYLEENDIAMINETETRAAZIJNZUUR",
"NATRIUMACETAAT 3-WATER (E 262)",
"POLYSORBAAT 20 (E 432)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"TALQUETAMAB"
],
"leaflet_url": null,
"authorised_at": "2023/08/21",
"procedure_number": "EMEA/H/C/005864",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1748",
"additional_monitoring": "Y"
}See everything about talquetamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.